Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine' [2]

Journal of Internal Medicine

Volumn 257, Issue 3, 2005, Pages 313-314

  Eriksson, Mats ^a   Angelin, B ^a   Sjoberg S ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYOGLOBIN; SIMVASTATIN;

AGED; ATHEROSCLEROSIS; CASE REPORT; CORONARY ARTERY DISEASE; DRUG FATALITY; EVIDENCE BASED MEDICINE; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LETTER; MYALGIA; PRIORITY JOURNAL; RHABDOMYOLYSIS;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; EVIDENCE-BASED MEDICINE; FATAL OUTCOME; FEMALE; HUMANS; RHABDOMYOLYSIS; SIMVASTATIN;

EID: 14844312062     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01453.x     Document Type: Letter

References (5)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
2. OTC statin: a bad decision for public health. Lancet 2004; 363: 1659.
3. Swedish Medical Products Agency. Treatment recommendations. Läkemedelsverket 2003; 14: 9-69.
4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610.
5. World Health Organization. Priority Medicines for Europe and the World. Geneva: WHO, 2004